Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [UCLA]

ABSTRACT: Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [UCLA]

PROVIDER: PRJNA632915 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [UCLA]

Project description:Background. We aimed to develop a gene expression-based prognostic signature for isocitrate dehydrogenase (IDH) wild-type glioblastoma using clinical trial datasets representative of glioblastoma clinical trial populations. Results. NanoString data were available from 512 patients in the discovery ATE dataset. Elastic net identified a prognostic signature of nine genes (CHEK1, GPR17, IGF2BP3, MGMT, MTHFD1L, PTRH2, SOX11, S100A9, and TFRC). Translating weighted elastic net scores to an average z-score signature conserved the prognostic value of the ATE signature. The z-score signature was prognostic for OS in the ATE dataset (P < 0.0001), as expected, and in the validation cohorts (AVAglio, P < 0.0001; GLARIUS, P = 0.021; UCLA, P = 0.0037). The signature remained prognostic following adjustment for MGMT promoter methylation status or corticosteroid use at baseline. A positive correlation between the signature and proneural/proliferative subtypes was observed in patients with MGMT non-methylated promoter status. Conclusions. The ATE signature showed prognostic value and may enable clinical trial stratification for IDH wild-type glioblastoma.

2020-06-01 | GSE150614 | GEO

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [ATE]

2020-06-01 | GSE149921 | GEO

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [GLARIUS]

2020-06-01 | GSE150612 | GEO

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [AVAglio]

2020-06-01 | GSE150604 | GEO

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma

Project description:Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma

| PRJNA632912 | ENA

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [ATE]

Project description:Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [ATE]

| PRJNA630493 | ENA

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [AVAglio]

Project description:Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [AVAglio]

| PRJNA632908 | ENA

Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [GLARIUS]

Project description:Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma [GLARIUS]

| PRJNA632910 | ENA

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Project description:This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled brain metastasis. The study will have three phases, Phase 1, Phase 2a and Phase 2b.

| 92735 | ecrin-mdr-crc

Bulk RNA-sequencing results of p16INK4A-high and -low glioblastoma, IDH-wild type, grade 4.

Project description:The expression of p16INK4A is widely used to identify fully senescent cells in noncancerous tissues, as well as senescent cancer cells in various types of cancer. In our study, we observed diffuse expression of p16INK4A in around 40 % of the patients with wild-type CDKN2A gene without mutation showing senescence phenotype, correlating with significant differences in overall survival between patients with high and low levels of p16INK4A expression. This prognostic distinction led us to hypothesize that cellular senescence in glioblastoma cells might confer a favorable effect on patient outcomes. To investigate the mechanism underlying this phenotype, we conducted RNA sequencing on 11 samples of glioblastoma, IDH-wild type along with corresponding in vivo and in vitro studies.

2024-05-10 | GSE266210 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data